Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial
Metastatic melanoma patients who were treated with patient-specific vaccines consisting of dendritic cells loaded with autologous tumor cells had a 5-year survival of over 50%. Enzyme-linked immunospot (ELISPOT) has been used to detect antigen reactive T cells as a means of determining immune respon...
Main Authors: | A. N. Cornforth, G. Lee, R. O. Dillman |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Journal of Biomedicine and Biotechnology |
Online Access: | http://dx.doi.org/10.1155/2011/635850 |
Similar Items
-
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
by: Robert O. Dillman, et al.
Published: (2018-03-01) -
Treatment of Cutaneous Ulcers with Multilayered Mixed Sheets of Autologous Fibroblasts and Peripheral Blood Mononuclear Cells
by: Takahiro Mizoguchi, et al.
Published: (2018-05-01) -
STRENGTHENING OF ORBITAL STUMP USING AUTOLOGOUS BLOOD MONONUCLEAR CELLS IN EXPERIMENT
by: I. V. Zapuskalov, et al.
Published: (2015-10-01) -
319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine
by: Gabriel Nistor, et al.
Published: (2020-11-01) -
Autologous Peripheral Blood Mononuclear Cells for Limb Salvage in Diabetic Foot Patients with No-Option Critical Limb Ischemia
by: Alessia Scatena, et al.
Published: (2021-05-01)